Longevity & AgingNew Therapies Are Reshaping Treatment for Relapsed Aggressive Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is curable in 60–70% of patients with standard immunochemotherapy, but the 30–40% who relapse have historically faced grim outcomes. This 2025 review from Huntsman Cancer Institute catalogs a wave of newly approved therapies—including CD20×CD3 bispecific antibodies (epcoritamab, glofitamab, odronextamab), antibody-drug conjugates (polatuzumab-vedotin, loncastuximab-tesirine), and CD19-directed CAR-T cell therapies—that are dramatically improving response rates and enabling durable remissions in heavily pretreated patients. The authors also outline emerging combination strategies and provide a practical treatment sequencing framework for clinicians navigating this increasingly complex landscape.
